Perspective
|
Open Access
Featured
-
-
Article |
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial
- Elena Élez
- , María Auxiliadora Gómez-España
- & Enrique Aranda
-
Article
| Open AccessRandomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression
- Baek-Yeol Ryoo
- , Ann-Li Cheng
- & Shukui Qin
-
Article
| Open AccessPhase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
- Thomas Decaens
- , Carlo Barone
- & Sandrine Faivre
-
Article |
The added value of H2 antagonists in premedication regimens during paclitaxel treatment
- Juul M. Cox
- , Leni van Doorn
- & Roelof W. F. van Leeuwen
-
Article
| Open AccessIntra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study
- Simon Pernot
- , Olivier Pellerin
- & Julien Taieb
-
Article
| Open AccessCovariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma
- Andrew Briggs
- , Bruno Daniele
- & Gabriel Tremblay
-
Consensus Statement
| Open AccessDevelopment of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK
- Robert A. Watson
- , Hugo De La Peña
- & Andrew S. Protheroe
-
Article
| Open AccessEfficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study
- Simon Pernot
- , Olivier Dubreuil
- & Julien Taieb
-
Clinical Study
| Open AccessImpact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study
- Leigh G Seamon
- , James J Java
- & Krishnansu S Tewari
-
Genetics and Genomics
| Open AccessWhole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma
- Hiroaki Itamochi
- , Tetsuro Oishi
- & Toru Sugiyama
-
Editorial |
Sequential versus concurrent chemotherapy for adjuvant breast cancer: does dose intensity matter?
- N LeVasseur
- & S K Chia
-
Translational Therapeutics
| Open AccessHuman equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma
- Bruno Vincenzi
- , Silvia Stacchiotti
- & Giuseppe Tonini
-
Clinical Study
| Open AccessPhase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment
- Richard Kim
- , E Gabriela Chiorean
- & David Portnoy
-
Clinical Study
| Open AccessA phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
- Glen J Weiss
- , Jordan Waypa
- & Vivek Khemka
-
Clinical Study
| Open AccessThe oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
- Rachna T Shroff
- , Mark Yarchoan
- & Nilofer S Azad
-
Translational Therapeutics
| Open AccessLithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling
- Sheng Han
- , Lingxuan Meng
- & Anhua Wu
-
Epidemiology
| Open AccessAcid-suppressing therapies and subsite-specific risk of stomach cancer
- E Christina M Wennerström
- , Jacob Simonsen
- & Charles S Rabkin
-
Letter to the Editor
| Open AccessComment on ‘Statin use and all-cancer survival: prospective results from the Women’s Health Initiative’
- Uffe Ravnskov
-
Clinical Study
| Open AccessCombination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial
- Roberto Pili
- , Glenn Liu
- & Michael A Carducci
-
Clinical Study
| Open AccessA phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
- Richard H Wilson
- , TR Jeffry Evans
- & Ruth Plummer
-
Translational Therapeutics
| Open AccessMT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib
- Cassandre Yip
- , Pierre Foidart
- & Agnès Noël
-
Translational Therapeutics
| Open AccessA combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition
- L M Schiffmann
- , M Brunold
- & O Coutelle
-
Molecular Diagnostics
| Open AccessThe predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004)
- Ananya Choudhury
- , Catharine M West
- & Nicholas James
-
Clinical Study
| Open AccessChemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
- Kristina Lindemann
- , Emma Gibbs
- & Gunnar Kristensen
-
Clinical Study
| Open AccessPhase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
- Adil Daud
- , Harriet M Kluger
- & Geoffrey I Shapiro
-
Translational Therapeutics
| Open AccessMathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients
- C Faivre
- , R El Cheikh
- & F Barlesi
-
Clinical Study
| Open AccessEfficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients
- Bum Jun Kim
- , Changhoon Yoo
- & Heung-Moon Chang
-
Short Communication
| Open AccessSerum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer
- Federica Marmorino
- , Lisa Salvatore
- & Chiara Cremolini
-
Translational Therapeutics
| Open AccessImpact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth
- Karla Parra
- , Paloma Valenzuela
- & Giulio Francia
-
Clinical Study
| Open AccessNon-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
- J L Kuiper
- , S M S Hashemi
- & E F Smit
-
Epidemiology
| Open AccessThe use of drugs acting on the renin–angiotensin system and the incidence of pancreatic cancer
- Victoria Mandilaras
- , Nathaniel Bouganim
- & Laurent Azoulay
-
Clinical Study
| Open AccessThe prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients
- Matteo Lambertini
- , Ana Catarina Pinto
- & Hatem A Azim Jr
-
Clinical Study
| Open AccessPatients’ and clinicians’ preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial
- Prunella Blinman
- , Linda Mileshkin
- & Martin R Stockler
-
Clinical Study
| Open AccessImpact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer
- Meinolf Karthaus
- , Ralf-Dieter Hofheinz
- & Claus-Henning Köhne
-
Clinical Study
| Open AccessDigoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer
- Kalle J Kaapu
- , Teemu J Murtola
- & Anssi Auvinen
-
Clinical Study
| Open AccessTTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials
- Dae-Won Lee
- , Myoung-Jin Jang
- & Tae-You Kim
-
Clinical Study
| Open AccessRADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases – results and lessons learnt
- Avinash Gupta
- , Corran Roberts
- & Mark R Middleton
-
Translational Therapeutics
| Open AccessEmergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib
- Aurelie Courtin
- , Tomoko Smyth
- & Nicola G Wallis
-
Clinical Study
| Open AccessA multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy
- A Kotsakis
- , A Matikas
- & V Georgoulias
-
Translational Therapeutics
| Open AccessMEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model
- C Marcela Diaz-Montero
- , Frances J Mao
- & Daniel J Lindner
-
Epidemiology
| Open AccessUse of sildenafil or other phosphodiesterase inhibitors and risk of melanoma
- Anton Pottegård
- , Sigrún Alba Johannesdottir Schmidt
- & Laurel A Habel
-
Translational Therapeutics
| Open AccessAcute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling
- Lauren CJ Baker
- , Jessica KR Boult
- & Simon P Robinson
-
Translational Therapeutics
| Open AccessCombined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer
- Gary Beale
- , Emma J Haagensen
- & Celine Cano
-
Translational Therapeutics
| Open AccessInsights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer
- Sophie Broutin
- , Adam Stewart
- & Udai Banerji
-
Translational Therapeutics
| Open AccessSuperior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer
- N V Rajeshkumar
- , Shinichi Yabuuchi
- & Manuel Hidalgo
-
Molecular Diagnostics
| Open AccessSystematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
- Cong Zhou
- , Andrew Clamp
- & Gordon C Jayson
-
Clinical Study
| Open AccessAdverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer
- Yongjun Cha
- , Kyung-Ju Kim
- & Tae-You Kim
-
Short Communication
| Open AccessAssociations of antibiotic use with risk of primary liver cancer in the Clinical Practice Research Datalink
- Baiyu Yang
- , Katrina Wilcox Hagberg
- & Katherine A McGlynn
-
Short Communication
| Open AccessPre-existing diabetes and lung cancer prognosis
- Juhua Luo
- , Michael Hendryx
- & Karen L Margolis